Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yabao Pharmaceutical Group CoSHSE:600351 -3.92%72 5-Year Yield-on-Cost % is 54.16 as of Aug. 21, 2026, which is 340% above its 10-year median of 12.32. GuruFocus rates SHSE:600351 with a GF Score™ of 72/100 and a GF Value™ of ¥5.70 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 507 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 98.62% on this metric.
The historical rank and industry rank for Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:600351'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.38 Med: 12.32 Max: 90.82
Current: 54.16
During the past 13 years, Yabao Pharmaceutical Group Co's highest Yield on Cost was 90.82. The lowest was 2.38. And the median was 12.32.
SHSE:600351's 5-Year Yield-on-Cost % is ranked better than 98.62% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs SHSE:600351: 54.16
Yabao Pharmaceutical Group Co (SHSE:600351) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Yabao Pharmaceutical Group Co 5-Year Yield-on-Cost % Related Terms
SHSE:600351 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yabao Pharmaceutical Group Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost % falls into.
Yabao Pharmaceutical Group Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Yabao Pharmaceutical Group Co (SHSE:600351) has a 5-Year Yield-on-Cost % of 54.16 as of Aug. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Yabao Pharmaceutical Group Co and its competitors. This is 340% above median its historical median of 12.32. Over the past decade, Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost % has ranged from 2.38 to 90.82. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #7 out of 507 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost % too high?
Yabao Pharmaceutical Group Co's current 5-Year Yield-on-Cost % of 54.16 is 340% above median its 10-year median of 12.32. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 90.82. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. Yabao Pharmaceutical Group Co's value of 54.16 is 2194.9% above this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #7 out of 507 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #7 out of 507 companies for 5-Year Yield-on-Cost %. This places Yabao Pharmaceutical Group Co in the top 1% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.36. Yabao Pharmaceutical Group Co's value of 54.16 is 2194.9% above this benchmark. Historically, Yabao Pharmaceutical Group Co's own 5-Year Yield-on-Cost % has ranged from 2.38 to 90.82 over the past decade. While the company's 10-year median is 12.32 vs. the industry median of 2.36, Yabao Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current 5-Year Yield-on-Cost % of 54.16 is 2194.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Yabao Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current 5-Year Yield-on-Cost % is 54.16, which is 340% above median its own 10-year median of 12.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.70, compared to a current price of ¥6.87 — trading 20.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 54.16, which is 340% above median its 10-year median of 12.32 and 2194.9% above the Drug Manufacturers industry median of 2.36. Yabao Pharmaceutical Group Co's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current 5-Year Yield-on-Cost % is 54.16 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥6.87 is trading 20.5% above its estimated GF Value™ of ¥5.70.
GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:600351:
5-Year Yield-on-Cost %: 54.16 (340% above median its 10-year median of 12.32)
GF Value™: ¥5.70 vs. price of ¥6.87 (20.5% above fair value)
Industry Position: 2194.9% above the Drug Manufacturers median (#7 of 507)
No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
72GF Score
Get the complete analysis for SHSE:600351
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600351 has been successfully added to your 
